Sterling Pharma Solutions acquires ADC Bio
Search jobs Sterling Pharma Solutions acquires ADC Bio
Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has announced the acquisition of ADC Biotechnology (ADC Bio), a UK based bioconjugation development services business specialising in antibody drug conjugates (ADCs).
This follows an announcement by Sterling in December of a strategic investment into the ADC Bio business, with a view to acquisition in 2021.
The Deeside, Wales, UK facility will rebrand to become part of the Sterling Pharma Solutions international network. Together the teams will establish a centre of excellence for bioconjugation and ADC development and manufacturing services, which combine Sterling’s 50 years of experience in cGMP manufacturing, quality processes and compliance, with the expertise of the ADC Bio team and the state of the art facilities available at Deeside.
Apr 6, 2021 3:31pm
CDMO Sterling wants to become a competitor in the arms race to find the latest and greatest cancer meds. (koto feja)
Just months after plugging a significant investment into U.K.-based antibody-drug conjugate specialist ADC Biotechnology, Sterling Pharma Solutions has made good on its promise to acquire the company.
Sterling said Tuesday it has purchased ADC, picking up the company s Deeside, Wales, R&D facility in the process. The plant will rebrand under the Sterling Pharma Solutions banner and become an ADC development and manufacturing center, Sterling said in a release.
The CDMO says it will start bioconjugation and ADC production at the plant in 2022. The company wants to position itself as a “competitive force in the oncological arms race, CEO Kevin Cook said in December when the company made its initial investment in ADC.